← Leaderboards
Xiaofeng Steven Zheng
Rutgers Biomedical And Health Sciences
$14,999,123
Attributed
$14,999,123
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,999,123 · 11
By mechanism
R01$14,563,690 · 9
P30$435,433 · 2
Top collaborators
No co-investigators on record.
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Tamara Minko$15,557,982
Others in their field
Top investigators on “Sirolimus”
- Valentin Fuster · Mount Sinai School Of Medicine Of Nyu$24,172,286
- Richard A. Miller · University Of Michigan At Ann Arbor$23,324,608
- Randy Strong · South Texas Veterans Health Care System$17,841,907
- David E Harrison · Jackson Laboratory$16,537,341
- David Michael Briscoe · Children'S Hospital Boston$16,289,072
- David M Sabatini · Whitehead Institute For Biomedical Res$16,271,502
Research focus
SirolimusMalignant NeoplasmsGrowthCell GrowthAntineoplastic AgentsSignal TransductionPathway InteractionsCancer CellInsightNutrientResponseCellsProtein KinaseMolecularCci-779Drug TargetingClinical TrialsCancer TherapyLeadMediatingResistanceGenetic TranscriptionInhibitor/AntagonistRegulation
Grant awards (56)
Oncogenic Chromatin Remodeling and Anticancer Mechanisms$453,067
R01 · FY2025 · CA · contact PI
Metabolic Control and Anticancer Mechanism$295,289
R01 · FY2025 · CA · contact PI
Cancer Pharmacology$269,566
P30 · FY2025 · CA · contact PI
Oncogenic Chromatin Remodeling and Anticancer Mechanisms$430,416
R01 · FY2024 · CA · contact PI
Metabolic Control and Anticancer Mechanism$88,490
R01 · FY2024 · CA · contact PI
Cancer Pharmacology$9,429
P30 · FY2024 · CA · contact PI
Oncogenic Chromatin Remodeling and Anticancer Mechanisms$453,067
R01 · FY2023 · CA · contact PI
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis$382,677
R01 · FY2023 · DK · contact PI
Metabolic Control and Anticancer Mechanism$334,338
R01 · FY2023 · CA · contact PI
Cancer Pharmacology$70,137
P30 · FY2023 · CA · contact PI
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis$382,677
R01 · FY2022 · DK · contact PI
Metabolic Control and Anticancer Mechanism$334,338
R01 · FY2022 · CA · contact PI
Cancer Pharmacology$19,847
P30 · FY2022 · CA · contact PI
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis$382,677
R01 · FY2021 · DK · contact PI
Metabolic Control and Anticancer Mechanism$341,161
R01 · FY2021 · CA · contact PI
Cancer Pharmacology$29,658
P30 · FY2021 · CA · contact PI
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis$380,739
R01 · FY2020 · DK · contact PI
Cancer Pharmacology$29,643
P30 · FY2020 · CA · contact PI
Cancer Pharmacology$7,153
P30 · FY2019 · CA · contact PI
Role of Rab1 in Cell Growth and Cancer$329,925
R01 · FY2017 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$329,925
R01 · FY2016 · CA · contact PI
Role of Rab1 in Cell Growth and Cancer$329,925
R01 · FY2016 · CA · contact PI
Growth Control and Anti-Cancer Drug Mechanisms$293,037
R01 · FY2016 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$329,925
R01 · FY2015 · CA · contact PI
Role of Rab1 in Cell Growth and Cancer$329,925
R01 · FY2015 · CA · contact PI
Growth Control and Anti-Cancer Drug Mechanisms$293,037
R01 · FY2015 · CA · contact PI
Role of Rab1 in Cell Growth and Cancer$320,027
R01 · FY2014 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$320,027
R01 · FY2014 · CA · contact PI
Growth Control and Anti-Cancer Drug Mechanisms$284,246
R01 · FY2014 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$24,335
R01 · FY2014 · CA · contact PI
Role of Rab1 in Cell Growth and Cancer$329,925
R01 · FY2013 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$259,901
R01 · FY2013 · CA · contact PI
Growth Control and Anti-Cancer Drug Mechanisms$239,441
R01 · FY2013 · CA · contact PI
Growth Control and Anti-Cancer Drug Mechanisms$74,745
R01 · FY2013 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$49,914
R01 · FY2013 · CA · contact PI
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer$327,850
R01 · FY2012 · CA · contact PI
Growth Control and Anti-Cancer Drug Mechanisms$287,508
R01 · FY2012 · CA · contact PI
Growth Control and Anti-Cancer Mechanisms$286,587
R01 · FY2011 · CA · contact PI
Growth Control and Anti-Cancer Mechanisms$295,450
R01 · FY2010 · CA · contact PI
Growth Control and Anti-Cancer Mechanisms$295,450
R01 · FY2009 · CA · contact PI
Growth Control and Anti-Cancer Mechanisms$295,450
R01 · FY2008 · CA · contact PI
Genetic and Molecular Basis of Rapamycin Sensitivity$422,405
R01 · FY2007 · CA · contact PI
Growth Control and Anti-Cancer Mechanisms$295,450
R01 · FY2007 · CA · contact PI
Genetic and Molecular Basis of Rapamycin Sensitivity$422,349
R01 · FY2006 · CA · contact PI
Genetic and Molecular Basis of Rapamycin Sensitivity$419,914
R01 · FY2005 · CA
Tor Signal Transduction to Gene Expression$261,240
R01 · FY2005 · GM
Genetic and Molecular Basis of Rapamycin Sensitivity$407,685
R01 · FY2004 · CA
Tor Signal Transduction to Gene Expression$261,240
R01 · FY2004 · GM
Genetic and Molecular Basis of Rapamycin Sensitivity$389,448
R01 · FY2003 · CA
Tor Signal Transduction to Gene Expression$257,040
R01 · FY2003 · GM
SIGNALING MECHANISMS BY THE TOR KINASE$153,806
R01 · FY2003 · CA
SIGNALING MECHANISMS BY THE TOR KINASE$92,229
R01 · FY2003 · CA
Tor Signal Transduction to Gene Expression$299,460
R01 · FY2002 · GM
SIGNALING MECHANISMS BY THE TOR KINASE$238,869
R01 · FY2002 · CA
SIGNALING MECHANISMS BY THE TOR KINASE$231,911
R01 · FY2001 · CA
SIGNALING MECHANISMS BY THE TOR KINASE$225,153
R01 · FY2000 · CA